Deutsche Bank
KALV

Deutsche Bank’s KalVista Pharmaceuticals KALV Stock Holding History

Deutsche Bank’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$782K Buy
38,857
+3,766
+11% +$60.7K ﹤0.01% 2332
2025
Q4 		$567K Buy
35,091
+4,836
+16% +$64K ﹤0.01% 2505
2025
Q3 		$369K Buy
30,255
+1,781
+6% +$24.6K ﹤0.01% 2708
2025
Q2 		$322K Sell
28,474
-3,652
-11% -$44.6K ﹤0.01% 2688
2025
Q1 		$371K Sell
32,126
-3,715
-10% -$37.9K ﹤0.01% 2644
2024
Q4 		$304K Buy
35,841
+13,923
+64% +$144K ﹤0.01% 2905
2024
Q3 		$254K Buy
21,918
+6,060
+38% +$76.2K ﹤0.01% 2803
2024
Q2 		$187K Buy
15,858
+3,662
+30% +$42.7K ﹤0.01% 2839
2024
Q1 		$145K Buy
12,196
+652
+6% +$8.69K ﹤0.01% 3005
2023
Q4 		$141K Sell
11,544
-335
-3% -$3.05K ﹤0.01% 3054
2023
Q3 		$114K Buy
11,879
+2,492
+27% +$25.5K ﹤0.01% 3100
2023
Q2 		$84.5K Sell
9,387
-5,736
-38% -$52.9K ﹤0.01% 3344
2023
Q1 		$119K Buy
15,123
+4,723
+45% +$35.2K ﹤0.01% 3247
2022
Q4 		$70.3K Buy
10,400
+162
+2% +$868 ﹤0.01% 3474
2022
Q3 		$149K Sell
10,238
-395
-4% -$5.52K ﹤0.01% 3120
2022
Q2 		$105K Sell
10,633
-2,219
-17% -$24.5K ﹤0.01% 3499
2022
Q1 		$189K Sell
12,852
-1,226
-9% -$17.6K ﹤0.01% 3303
2021
Q4 		$186K Sell
14,078
-1,630
-10% -$25.9K ﹤0.01% 3425
2021
Q3 		$274K Buy
15,708
+3,617
+30% +$73.3K ﹤0.01% 3397
2021
Q2 		$289K Sell
12,091
-384
-3% -$10K ﹤0.01% 3567
2021
Q1 		$320K Buy
12,475
+1,763
+16% +$46.3K ﹤0.01% 3376
2020
Q4 		$203K Buy
10,712
+3,116
+41% +$53.4K ﹤0.01% 3460
2020
Q3 		$95K Buy
7,596
+849
+13% +$10.6K ﹤0.01% 3577
2020
Q2 		$82K Buy
6,747
+2,411
+56% +$25.6K ﹤0.01% 3553
2020
Q1 		$33K Sell
4,336
-262
-6% -$3.54K ﹤0.01% 3734
2019
Q4 		$81K Sell
4,598
-4,159
-47% -$54.3K ﹤0.01% 3680
2019
Q3 		$101K Sell
8,757
-529
-6% -$8.55K ﹤0.01% 3549
2019
Q2 		$204K Sell
9,286
-8,501
-48% -$199K ﹤0.01% 3811
2019
Q1 		$508K Buy
17,787
+17,618
+10,425% +$382K ﹤0.01% 3439
2018
Q4 		$3K Sell
169
-7,922
-98% -$159K ﹤0.01% 5036
2018
Q3 		$179K Sell
8,091
-17,137
-68% -$232K ﹤0.01% 4284
2018
Q2 		$205K Sell
25,228
-18,017
-42% -$159K ﹤0.01% 4274
2018
Q1 		$409K Sell
43,245
-40,759
-49% -$427K ﹤0.01% 3822
2017
Q4 		$819K Buy
84,004
+83,999
+1,679,980% +$874K ﹤0.01% 3329
2017
Q3 		$0 Hold
5
– – ﹤0.01% 4977
2017
Q2 		$0 Hold
5
– – ﹤0.01% 5023
2017
Q1 		$0 Hold
5
– – ﹤0.01% 5011
2016
Q4 		$0 Sell
5
-6,861
-100% -$50.6K ﹤0.01% 4989
2016
Q3 		$44K Buy
+6,866
New +$51.7K ﹤0.01% 4259
2016
Q2 		– Sell
-129
Closed -$1K – 5266
2016
Q1 		$1K Sell
129
-109
-46% -$1.95K ﹤0.01% 5089
2015
Q4 		$11K Sell
238
-25
-10% -$1.31K ﹤0.01% 4905
2015
Q3 		$13K Buy
263
+31
+13% +$2.64K ﹤0.01% 4890
2015
Q2 		$23K Buy
+232
New +$23K ﹤0.01% 4874

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank's KALV Position: Q1 2026 in Review

Deutsche Bank increased its KalVista Pharmaceuticals (KALV) stake by 11% in Q1 2026, buying an estimated $60.7K and bringing the position to 38,857 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Deutsche Bank first reported a position in KALV in Q2 2015 and has held it in 43 quarters since. The position peaked at $819K in Q4 2017. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Deutsche Bank held 38,857 shares of KalVista Pharmaceuticals worth $782K as of Q1 2026.
  • Deutsche Bank bought 3,766 KalVista Pharmaceuticals shares in Q1 2026, an estimated $60.7K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2332 holding.
  • Deutsche Bank first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 43 quarters since.
  • Deutsche Bank's KalVista Pharmaceuticals position peaked at $819K in Q4 2017.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.